In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $1.38.
Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Merck & Company, and Nektar Therapeutics. According to TipRanks, Goldstein has an average return of -3.7% and a 32.32% success rate on recommended stocks.
Nektar Therapeutics has an analyst consensus of Hold, with a price target consensus of $3.50, a 153.62% upside from current levels. In a report released on February 24, SVB Securities also assigned a Hold rating to the stock with a $3.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $11.39 and a one-year low of $1.38. Currently, Nektar Therapeutics has an average volume of 2.11M.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NKTR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
Read More on NKTR:
- Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
- Nektar price target lowered to $3 from $5 at SVB Securities
- Nektar Plunges after Topline Data Misses Primary Endpoint
- Nektar downgraded to Underperform from Hold at Jefferies
- Nektar down 31% afterhours after update on rezpegaldesleukin in lupus
